Jiang, S., Pu, X., Wu, L., Luo, Y., Wang, Q., Zhou, J., Jiang, G., Bu, Q., Li, M., Li, J., Zou, J., Zhang, Y., Chu, Q., Liu, P., Ma, F., Zhang, R., Zhuang, L., Mo, Y., Li, J., Xie, N. (2026). A real-world analysis of dyslipidemia and attributable risk in lorlatinib-treated ALK-positive lung cancer patients.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e24190